Illumina completed the acquisition of SomaLogic from Standard BioTools for $425m.

Illumina, a genomics company, completed the acquisition of SomaLogic, a provider of proteomics technology, from Standard BioTools, a life sciences tools company, for $425m. "Welcoming the SomaLogic team to Illumina is an important milestone in executing the multiomics strategy we outlined in 2024. By combining SomaLogic's highly differentiated proteomics technology with Illumina's industry-leading innovation and global reach, we are strengthening our ability to deliver scalable insights across genomics and proteomics, helping customers unlock more from every sample in support of better outcomes for patients."Jacob Thaysen, Illumina CEO.